ClinicalTrials.gov identifier
TNBC, germline BRCA mutations
TRIPLE-NEGATIVE BREAST CANCER
NCT03499353The undetermined efficacy of the current standard-of-care neoadjuvant treatment of early-stage triple-negative breast cancer (TNBC) with germline BRCA mutations emphasizes the need for biomarker-targeted treatment in this setting. This article evaluates the efficacy and safety of neoadjuvant talazoparib in patients with germline 